Diabetes Obes Metab. 2010 Sep;12(9):825-8. doi: 10.1111/j.1463-1326.2010.01234.x.
We conducted a three-arm, parallel-group, randomized, controlled trial to compare the effects of rosiglitazone and physical exercise on endothelial function in patients with coronary artery disease and impaired fasting glucose or impaired glucose tolerance over a 6-month period. Group A received rosiglitazone tablets 8 mg daily (n = 16), group B underwent a structured physical exercise programme (n = 15) and group C served as a control group (n = 12). At baseline and after 6 months, brachial artery ultrasound imaging was performed to assess reactive flow-mediated dilation (FMD). Rosiglitazone treatment and exercise both led to significant improvements in insulin resistance at 6 months, whereas no change was observed in control patients. FMD improved significantly in physical exercise patients, whereas no change could be observed in patients receiving rosiglitazone or in the control group. Between-group comparisons also showed a significant relative improvement in FMD in exercise patients compared with rosiglitazone.
我们进行了一项三臂、平行组、随机对照试验，比较了罗格列酮和体育锻炼对伴有空腹血糖受损或糖耐量受损的冠心病患者内皮功能的影响，为期 6 个月。A 组每天服用罗格列酮片 8 毫克（n = 16），B 组进行了结构化的体育锻炼计划（n = 15），C 组为对照组（n = 12）。在基线和 6 个月时，进行肱动脉超声成像以评估反应性血流介导的扩张（FMD）。罗格列酮治疗和运动均导致 6 个月时胰岛素抵抗显著改善，而对照组患者无变化。运动组患者的 FMD 显著改善，而接受罗格列酮或对照组患者则无变化。组间比较还显示，与罗格列酮相比，运动组患者的 FMD 相对改善更为显著。
